10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Thursday, July 15, 2010

Twilight Litaka Pharma Ltd:-Buy/sell/hold,growth prospects and recomendation,news and results,target price and analysis,views and outlook

Twilight Litaka Pharma was recommended at 24rs an year odd ago.Today it went on to hit a high of 185rs providing a staggering 750% return.Check the link if you missed the previous story:-

Scripscan:Twilight Litaka Pharma Ltd

Story:Mumbai-based Twilight Litaka Pharma is engaged in the business of manufacturing drug formulations and nutraceuticals.With the domestic pharma industry growing at 12% per annum, the company’s growth prospects over the next 2-3 years look attractive.Incorporated in 1974, the company was formerly called Li Taka Pharmaceuticals. It operationally merged with Care Unipac in October ’05 to form Twilight Litaka Pharma. It manufactures various therapeutic drugs in the form of tablets, capsules, liquids and ointments. The company has three manufacturing plants in Maharashtra, and one in Baddi, Himachal Pradesh.Contract manufacturing and loan licensing account for around 50% of the company’s revenues.It has contract manufacturing or loan licensing arrangements with companies like Novartis, Cipla, Wockhardt, Pfizer, Lupin and Serum. 35-40% of the company’s revenues come from domestic sales of its formulations, while the remaining 10-15% is contributed by export sales. The company sells over 120 formulations through its 1,000+ marketing personnel and sells its products in 35 countries. It also has an exclusive marketing arrangement with Cipla to market its brands across 10 states.It aims to achieve a turnover of Rs 500 crore by ’09-10. The proposed plant in Sikkim is likely to enjoy a 20-year excise tax benefit.The company is also trying to hedge against risks faced by the pharma industry.The company has been an outperformer in its sector and I see great chances of the scrip catching investors fancy going forward.Its my bet in the pharma sector,so folks go and buy it.

Latest update:Twilight is in a momentum now may hit higher levels.Enjoy the 7 bagger folks.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner